Elevation Oncology, Inc. financial data

Symbol
ELEV on Nasdaq
Location
101 Federal Street, Suite 1900, Boston, MA
Fiscal year end
December 31
Latest financial report
10-Q - Q1 2025 - May 15, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2.28K % +26.7%
Debt-to-equity 55.1 % +2.13%
Return On Equity -74.7 % -25.8%
Return On Assets -48.1 % -24.9%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 59.2M shares +8.38%
Common Stock, Shares, Outstanding 59.2M shares +14.6%
Common Stock, Value, Issued 6K USD +20%
Weighted Average Number of Shares Outstanding, Basic 59.2M shares +14.2%
Weighted Average Number of Shares Outstanding, Diluted 59.2M shares +14.2%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 29.5M USD +22%
General and Administrative Expense 16.2M USD +12.5%
Operating Income (Loss) -49.1M USD -27.2%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -48M USD -22%
Income Tax Expense (Benefit) 38K USD +5.56%
Net Income (Loss) Attributable to Parent -48M USD -21.9%
Earnings Per Share, Basic -1 USD/shares -9.46%
Earnings Per Share, Diluted -1 USD/shares -9.46%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 60.5M USD -33.3%
Marketable Securities, Current 20.2M USD +50.3%
Assets, Current 82.2M USD -23.8%
Property, Plant and Equipment, Net 29K USD -40.8%
Other Assets, Noncurrent 0 USD -100%
Assets 82.2M USD -24.5%
Accounts Payable, Current 492K USD +13.1%
Accrued Liabilities, Current 3.74M USD +97.2%
Liabilities, Current 4.24M USD +81.5%
Liabilities 35.5M USD +7.08%
Accumulated Other Comprehensive Income (Loss), Net of Tax 11K USD
Retained Earnings (Accumulated Deficit) -255M USD -23.2%
Stockholders' Equity Attributable to Parent 46.7M USD -38.4%
Liabilities and Equity 82.2M USD -24.5%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -12.7M USD -32.8%
Net Cash Provided by (Used in) Investing Activities 23.8M USD +14.8%
Common Stock, Shares Authorized 500M shares 0%
Common Stock, Shares, Issued 59.3M shares +14.7%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 11M USD -73.3%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 60.5M USD -33.3%
Interest Paid, Excluding Capitalized Interest, Operating Activities 806K USD -9.13%
Deferred Tax Assets, Valuation Allowance 60.3M USD +31.3%
Deferred Tax Assets, Gross 60.3M USD +31.3%
Depreciation 5K USD -50%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -48M USD -22.1%
Deferred Tax Assets, Operating Loss Carryforwards 26.5M USD +30.9%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 302M USD +6.7%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 4K USD +33.3%
Share-based Payment Arrangement, Expense 4.37M USD +57.4%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%